Please use this identifier to cite or link to this item: http://repository.kln.ac.lk/handle/123456789/1160
Full metadata record
DC FieldValueLanguage
dc.contributor.authorde Silva, H.J.en_US
dc.contributor.authorWijewickrema, R.en_US
dc.contributor.authorSenanayake, N.en_US
dc.date.accessioned2014-10-29T09:10:26Z
dc.date.available2014-10-29T09:10:26Z
dc.date.issued1992en_US
dc.identifier.citationLancet. 1992; 339(8802): pp.1136-1138en_US
dc.identifier.issn0140-6736 (Print)en_US
dc.identifier.issn1474-547X (Electronic)en_US
dc.identifier.urihttp://repository.kln.ac.lk/handle/123456789/1160
dc.descriptionIndexed in MEDLINE
dc.description.abstractAcute organophosphorus (OP) poisoning is usually treated with atropine plus cholinesterase reactivators such as oximes, but controlled trials to assess the efficacy of oximes in OP poisoning have not been done. A period when the acetyl cholinesterase reactivator pralidoxime chloride was not available in Sri Lanka gave us the opportunity to compare atropine alone for treatment of moderate to severe OP poisoning (21 patients) with atropine plus pralixodime (24 patients). Outcome, as assessed clinically, was similar in the two groups. These results cast doubt on the necessity of cholinesterase reactivators for treatment of acute OP poisoning.en_US
dc.publisherLancet Publishing Groupen_US
dc.subjectPoisoning
dc.subjectPoisoning-drug therapy
dc.subjectPoisoning-epidemiology
dc.subjectPoisoning-mortality
dc.subjectOrganophosphate Poisoning
dc.subjectAtropine-therapeutic use
dc.subjectCholinesterase Reactivators-therapeutic use
dc.subjectPralidoxime Compounds-therapeutic use
dc.subjectClinical Trial
dc.subjectControlled Clinical Trial
dc.subjectSri Lanka-epidemiology
dc.titleDoes pralidoxime affect outcome of management in acute organophosphorus poisoning?en_US
dc.typeArticleen_US
dc.identifier.departmentMedicineen_US
Appears in Collections:Journal/Magazine Articles

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.